<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044486</url>
  </required_header>
  <id_info>
    <org_study_id>P01899</org_study_id>
    <nct_id>NCT00044486</nct_id>
  </id_info>
  <brief_title>Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)</brief_title>
  <official_title>A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This trial is in high risk patients to determine the safety and efficacy of posaconazole vs.&#xD;
      fluconazole in the prophylaxis against development of invasive fungal infections.&#xD;
&#xD;
      Profound, prolonged neutropenia (Absolute neutrophil count&lt;500 cells/cubic mm for at least 7&#xD;
      days) due to induction chemotherapy for acute myelogenous leukemia, or myelodysplastic&#xD;
      syndrome.&#xD;
&#xD;
      Treatment Duration: maximum of 12 weeks Follow-Up 2 months. Endpoints: incidence of proven or&#xD;
      probable IFI according to EORTC/MSG criteria within the neutropenic episode and within 100&#xD;
      days of randomization as determined by external expert review.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to determine the safety, tolerance and efficacy of POZ used as&#xD;
      prophylaxis if IFI in high-risk subjects with prolonged profound neutropenia. The primary&#xD;
      objective is to assess the efficacy of SCH 56592 vs fluconazole and itraconazole in&#xD;
      preventing proven or probable IFI during neutropenic episodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">602</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Neutropenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole oral suspension</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults or adolescents (age&gt;13 years) and weight&gt; 34kg, either gender&#xD;
&#xD;
          -  Disease definition: Anticipated or documented prolonged neutropenia (ANC&lt;500/mm3 2)&#xD;
             Eastern Cooperative Oncology Group (ECOG) performance score of less than 3.&#xD;
&#xD;
          -  Female subjects of childbearing age must be using a medically accepted method of birth&#xD;
             control before beginning study-drug treatment and agree to continue its use during the&#xD;
             study or be surgically sterilized (eg, hysterectomy or tubal ligation).&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             (beta-hcG) at Baseline or within 72 hours before the start of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant, intend to become pregnant, or are nursing.&#xD;
&#xD;
          -  Excluded prior treatments: Subjects previously treated with AMB, FLZ, or ITZ for&#xD;
             proven or probable IFI within 30 days of enrollment.&#xD;
&#xD;
          -  Excluded treatments prior to specific study phases: Subjects who have taken the&#xD;
             following drugs: those known to interact with azoles and that may lead to&#xD;
             life-threatening side effects.&#xD;
&#xD;
          -  Subjects who have used any investigational drugs or biologic agents other than their&#xD;
             chemotherapy regimens within 30 days of study entry.&#xD;
&#xD;
          -  Subjects who are participating in any other blinded clinical study within 30 days of&#xD;
             study entry.&#xD;
&#xD;
          -  Subjects with renal insufficiency (estimated creatinine clearance less than 20&#xD;
             mL/minute at Baseline or likely to require dialysis during the study).&#xD;
&#xD;
          -  Subjects having an ECG with a prolonged QTc interval by manual reading: QTc greater&#xD;
             than 450 msec for men and greater than 470 msec for women.&#xD;
&#xD;
          -  Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate&#xD;
             aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase levels&#xD;
             greater than 5 times the upper limit of normal (ULN), or a total bilirubin level&#xD;
             greater than 3 times the ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>Ecuador</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 29, 2002</study_first_submitted>
  <study_first_submitted_qc>September 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2002</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>neutropenia</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>fungal infections</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Anticipated prolonged profound neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

